ARDX
Ardelyx Inc.
$6.16
+$0.06(+0.90%)
41
Overall
40
Value
41
Tech
44
Quality
Market Cap
$1.46B
Volume
2.09M
52W Range
$3.21 - $8.40
Target Price
$16.10
Company Overview
| Mkt Cap | $1.46B | Price | $6.16 |
| Volume | 2.09M | Change | +0.90% |
| P/E Ratio | -37.3 | Open | $6.05 |
| Revenue | $333.6M | Prev Close | $6.10 |
| Net Income | $-39.1M | 52W Range | $3.21 - $8.40 |
| Div Yield | N/A | Target | $16.10 |
| Overall | 41 | Value | 40 |
| Quality | 44 | Technical | 41 |
No chart data available
About Ardelyx Inc.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ARDX | $6.16 | +0.9% | 2.09M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |